Brevan Howard Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Brevan Howard Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$409K	Buy	+133,315	New	+$515K	﹤0.01%	1425
2025 Q4	–	Sell	-30,159	Closed	-$147K	–	2213
2025 Q3	$147K	Sell	30,159 -83,039	-73%	-$436K	﹤0.01%	1815
2025 Q2	$573K	Sell	113,198 -143,803	-56%	-$706K	﹤0.01%	1301
2025 Q1	$1.36M	Buy	257,001 +216,910	+541%	+$1.58M	0.01%	395
2024 Q4	$271K	Buy	+40,091	New	+$270K	﹤0.01%	814
2024 Q2	–	Sell	-21,096	Closed	-$210K	–	1360
2024 Q1	$210K	Buy	+21,096	New	+$235K	﹤0.01%	784

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Brevan Howard Capital Management's RXRX Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 133,315 shares worth $409K. The stake represents ﹤0.01% of the portfolio and ranks #1425 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in RXRX as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in RXRX in Q1 2024 and has held it in 6 quarters since. The position peaked at $1.36M in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Brevan Howard Capital Management held 133,315 shares of Recursion Pharmaceuticals worth $409K as of Q1 2026.
Recursion Pharmaceuticals was a new Brevan Howard Capital Management position in Q1 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1425 holding.
Brevan Howard Capital Management first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
Brevan Howard Capital Management's Recursion Pharmaceuticals position peaked at $1.36M in Q1 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.